Indian drugmakers have launched semaglutide formulations after the patent expired in India on March 20, opening the market to lower-cost versions of the diabetes and weight-loss drug sold globally as ...

Novo Nordisk will lose patent protection for its blockbuster drug Ozempic in several major markets from Saturday. The patent expiry opens the door for other manufacturers to produce cheaper generic ...

A massive shake-up is underway in India's obesity and diabetes drug market as the patent for Semaglutide—the key ingredient behind blockbuster drugs—expires. This opens the floodgates for over 40 ...

The expected arrival of generic versions of semaglutide -- the active ingredient in Ozempic and Wegovy -- is poised to force a rethink of how Canadian insurers handle obesity treatments. At present, ...